Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients admitted for acute coronary syndrome or acute myocardial infarction requiring active treatment with aspirin clopidogrel and (enoxaparin or thrombolytics.)~Exclusion Criteria:~* known active peptic ulcer disease or gastrointestinal within 8 wk~* known iron deficiency anemia with Hb \< 10 gm/dl~* mechanical ventilation~* active cancer, liver cirrhosis, end-stage renal failure~* life expectancy \< 1 yr~* known allergic to aspirin, clopidogrel, enoxaparin famotidine or esomeprazole~* pregnancy, lactation, child-bearing potential in the absence of contraception,~* co-prescription of NSAID, corticosteroid, or warfarin~* non-oral feeding or impaired GI absorption e.g. vomiting~* already on proton pump inhibitor for \> 1 day or another clinical trial drug for ulcer disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): oral esomeprazole 20 mg daily
- 2 (Type: ACTIVE_COMPARATOR): oral famotidine 40mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).